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Objectives: The superiority of hyperpolarized arrest with adenosine triphos- 
phate-sensitive potassium channel openers over standard hyperkalemic depo- 
larizing cardioplegia during normothermic ischemia has been documented. 
This study examined the hypothesis that pinacidil would provide superior 
protection in a more clinically relevant model of an acutely injured heart and 
hypothermic ardioplegic arrest. Methods: In a blood-perfused, parabiotic, 
rabbit heart Langendorff model, hearts underwent 15 minutes of unprotected 
global normothermic schemia before the administration of 50 ml of cardiople- 
gic solution at 4 ° C, followed by 50 minutes of hypothermic (15 ° C) ischemia 
and 30 minutes of reperfusion. The cardioplegic solutions administered 
consisted of Krebs-Henseleit solution alone (N = 6), Krebs-Henseleit solution 
with pinacidil (50 b~mol/L; N = 10), Krebs-Henseleit solution with pinacidil (50 
/~mol/L) and glibenclamide (a potassium channel blocker, 10 #mol/L; N = 8), 
or St. Thomas' Hospital solution (N = 8). The percent recovery of developed 
pressure, linear diastolic pressure-volume r lationships, and coronary blood 
flow were compared. Results: The percent recovery of developed pressure was 
32.8% - 2.8%, 43.0% -+ 4.3%, 46.5% --+ 2.2%, and 49.3% -_. 2.7% for the 
Krebs-Henseleit, the Krebs-Henseleit with pinacidil and glibenclamide, the St. 
Thomas' Hospital, and the Krebs-Henseleit with pinacidil groups, respectively. 
No hearts had ventricular fibrillation on reperfusion. Conclusions: During 
hypothermic hyperpolarized arrest, as opposed to normothermic schemia as 
in our previous tudies, there was neither an increased incidence of ventricular 
fibrillation nor prolonged electrical activity when compared with results during 
traditional hyperkalemic arrest. Myocardial protection by St. Thomas' Hospi- 
tal solution and pinacidil was superior (p = 0.009) to that with Krebs- 
Henseleit solution alone. The protection provided by pinacidil was lost with the 
addition of glibenclamide, indicating that the drug has adenosine triphos- 
phate-sensitive potassium channel activity during hypothermia. (J Thorac 
Cardiovasc Surg 1997;113:567-75) 
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T he myocyte action potential is generated by the opening and closing of ion channels in the plasma 
membrane]  During myocardial ischemia, there are 
profound changes in the action potential  including a 
decrease in the resting membrane  potential, a de- 
crease in the rate of rise of the action potential 
upstroke, and a decrease in the action potential 
duration.2, 3 A unique metabolically sensitive potas- 
sium channel has been shown to be responsible for 
many of these electrophysiologic changes. 3 Noma 4 
first described this potassium channel in guinea pig 
and rabbit ventricular myocytes and demonstrated 
that it was inhibited by intracellular adenosine 
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triphosphate (ATP) and opened during times of 
ischemia. The opening of this ATP-sensitive potas- 
sium (KATP) channel causes an outward potassium 
current hat hyperpolarizes the cell membrane. This 
results in a significant shortening Of the duration of 
the plateau phase of the action potential, during 
which most of the inward calcium transport occurs. 
This reduction in calcium influx causes a decrease in 
contractility. Activation of KAT e channels has been 
shown to underlie the contractile failure seen during 
periods of ischemia and metabolic inhibition. 5This 
decrease in mechanical activity conserves ATP and 
thus is cardioprotective. 4 
Previous Work from our laboratory has demon- 
strated the benefit of the ATP-sensitive potassium 
channel openers (PCOs) pinacidil and aprikalim as 
cardioplegic agents during normothermic ischemia 
in our blood-perfused, isolated rabbit heart model. 
During normothermic ischemia, aprikalim was 
shown to provide superior myocardial protection 
compared with 20 mmol KC1 in Krebs-Henseleit 
solution, and pinacidil was shown to provide equiv- 
alent myocardial protection compared with 20 mmol 
KC1 in Krebs-Henseleit solution and with St. 
Thomas' Hospital solution. 6-8 The optimal dose of 
pinacidil was determined to be 50 /xmol/L. 7 A 
shortcoming of these studies was that they examined 
potassium channel opener cardioplegia only during 
normothermic global ischemia in normal hearts. 
However, many cardiac surgeons still use some 
degree of hypothermia to protect the heart during 
cardioplegic arrest. Operations also are often com- 
plicated by acute ongoing ischemia, such as seen 
after angioplasty failure. In an effort to evaluate 
pinacidil in a more clinically relevant model, the 
current study was designed to compare myocardial 
protection with pinacidil (50/xmol/L), pinacidil with 
glibenclamide (10 txmol/L; a potassium channel 
inhibitor), and St. Thomas' Hospital solution during 
hypothermic ischemia in an acutely injured heart. 
Material and methods 
Experimental preparation. Adult New Zealand White 
rabbits of either sex weighing 3.0 to 5.0 kg were anesthe- 
tized intramuscularly with acepromazine (1 mg/kg) and 
xylazine (17.5 mg/kg), followed by ketamine (62.5 mg/kg). 
Each study involved a support animal and a study animal. 
The support animal was heparlnized (2500 U) via an ear 
vein and underwent cannulation of the left carotid artery, 
the left internal jugular vein, and the left femoral artery. 
The femoral cannula was connected to a pressure trans- 
ducer (model P231D, Gould Inc., Cleveland, Ohio) and 
blood pressure was monitored continuously on a Gould 
ES1000 system. The carotid arterial cannula was attached 
to silicone rubber tubing (internal diameter 0.125 inch, 
Baxter Scientific Products, McGaw Park, Ill.) and the 
blood actively pumped (Masterflex model 7013 pump, 
Cole-Palmer Int., Chicago) to perfuse amodified Langen- 
dorff apparatus, which has been described previously. 8 
The height of the column was 80 cm H20. The venous 
return from the Langendorff column was returned to the 
internal jugular vein of the support animal with use of a 
Travenol pump (model 5Ml155, Travenol Laboratories, 
Inc., Deerfield, Ill.). The lungs of the support animal were 
ventilated (model 683, Harvard Apparatus, South Natick, 
Mass.) via a tracheostomy with 100% 0 2 throughout the 
experiment. 
After support animal preparation was completed, the 
donor animal was heparinized and the lungs ventilated via 
a tracheostomy. The animal then underwent rapid ster- 
notomy and cardiectomy. The aorta was cannulated and 
coronary perfusion instituted via the Langendorff column. 
The support animal was given indomethacin (1 mg/kg) 
intravenously to promote blood pressure stability. 9 The 
systolic arterial blood pressure of the support animal was 
maintained higher than 65 mm Hg by transfusion with 
Plasma-Lyte solution (Baxter Healthcare Corp., Deer- 
field, Ill.) or blood collected from the donor animal at the 
time of cardiectomy. Values of arterial blood gases, 
electrolytes, and the hematocrit of the support animal 
were monitored at regular intervals and maintained within 
physiologic limits. The support animal was given supple- 
mental anesthesia ntramuscularly asneeded throughout 
the experiment. Heparin (500 U) was given to the support 
animal at hourly intervals. 
After aortic cannulation, a left atriotomy was done and 
a vent (polyethylene tubing, internal diameter 0.86 mm, 
Clay Adams, Parsippany, N.J.) was placed into the left 
ventricle. A fluid-filled latex balloon was placed into the 
left ventricle and secured with a purse-string suture in the 
mitral anulus. The balloon was connected to a pressure 
transducer (model 42559-01, Abbott Laboratories, North 
Chicago, Ill.) and to a Gould amplifier (model 134615-50, 
Gould). The zero pressure reference was set at the level of 
the aortic valve. Two right atrial electrodes were posi- 
tioned and connected to a pacemaker (model DTU101, 
Bloom Associates Ltd., Reading, Pa.). The heart was 
paced at a constant rate (180 to 240 beats/min) through- 
out the study. Two left ventricular epicardial bipolar 
electrodes were positioned and connected to a preampli- 
fier (model 11-G5407-58, Gould) and to a universal 
amplifier (model MU13-4615-58, Gould) and filtered be- 
tween 0.05 and 1000 Hz. 
The pressure and electrogram waveforms were dis- 
played continuously on an oscilloscope (Gould ES1000) 
and digitized on-line with use of an AT-CODAS system 
(DATAQ Instruments, Akron, Ohio) at a sampling rate of 
1000 Hz. 
The heart was enclosed in an air bath surrounded by a 
glass-jacketed water beaker. Myocardial temperature was 
monitored throughout the experiment with a temperature 
probe (model 0112, Shiley Inc., Irvine, Calif.) placed in 
the right ventricle and was controlled by adjusting the 
water bath temperature (model 71, Polyscience, Niles, 
Ill.). Myocardial temperature was maintained at 37°C 
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throughout the experiment except during the 50-minute 
ischemic period when the heart was maintained between 
12.5 ° and 16.6 ° C with use of a second in-line water bath 
(model 9010, Fisher Scientific, Pittsburgh, Pa.). Coronary 
flow was monitored with an in-line flow probe (model 2N, 
Transonic Systems, Ithaca, N.Y.) and an ultrasonic blood 
flow meter (model 101, Transonic Systems). 
Experimental protocol. Hearts were excluded from 
study if they did not obtain a developed pressure of 80 mm 
Hg at an end-diastolic pressure of 10 mm Hg or if the 
baseline developed pressure did not remain stable during 
the 30 minutes after instrumentation. 
After a 30-minute quilibration period, the left ventric- 
ular pressure-volume r lationships were measured. A 
wide range of volumes was infused into the intraventric- 
ular latex balloon to generate end-diastolic pressures 
(EDPs) of 0, 2..5, 5, 10, 15, and 20 mm Hg. After baseline 
data acquisition, fluid was adjusted in the latex balloon to 
obtain an EDP of 5 mm Hg before the ischemic period. 
All hearts underwent a 15-minute period of unpro- 
tected, global, normothermic schemia. This was followed 
immediately by infusion of cardioplegic solution. Thirty- 
two hearts were randomly assigned to receive a different 
cardioplegic solution for myocardial protection during a 
50-minute period of global hypothermic schemia. Hyper- 
polarizing cardioplegic solution consisted of Krebs- 
Henseleit solution (in millimolars per liter distilled water: 
NaCI, 118.5; NaHCO3, 25.0; KC1, 3.2; MgSO4, 1.2; 
KH2PO4, 1.2; glucose, 5.5; CaC12, 2.5) with pinacidil (50 
/xmol/L, N = 8). Depolarizing cardioplegic solution con- 
sisted of St. Thomas' Hospital solution (N = 8). A control 
group received Krebs-Henseleit solution alone (N = 6), 
and a final group received Krebs-Henseleit solution with 
pinacidil (50 ~Lmol/L) and glibenclamide (a potassium 
channel blocker, 10 /xmol/L; Sigma Chemical Co., St. 
Louis, Mo.; N = 8). Heparin (12.5 U/ml) was added to 
each of the cardioplegic solutions. Pinacidil was provided 
by Leo Pharmaceuticals, Ballerup, Denmark. St. Thomas' 
Hospital solution was provided by Abbott Laboratories. 
Sodium bicarbonate (8.4%) was added to the St. Thomas' 
Hospital solution before each infusion of cardioplegic 
solution (0.5 ml/50 ml) to correct he pH to 7.8. 
After the 15-minute period of global, normothermic 
ischemia, 50 ml of hypothermic (4 ° C) cardioplegic solu- 
tion was infused from a height of 80 cm H20 via a 
separate column. The cardioplegic solution effluent was 
collected and discarded. Both the time until cessation of 
mechanical activity and the time until electrical quies- 
cence were recorded. Cessation of mechanical ctivity was 
defined as the absence of a developed pressure. 
After 50 minutes of hypothermic global ischemia, the 
Langendorff column was unclamped and the heart reper- 
fused for 30 minutes. If ventricular fibrillation persisted 
after reperfusion, the heart was defibrillated (model D84, 
Electrodyne Co., Inc., Westwood, Mass.). Electrolyte, 
hematocrit, and arterial blood gas measurements of the 
support animal were repeated to ensure stability. After 30 
minutes of reperfusion, data were collected at the identi- 
cal balloon volumes used during baseline preischemic data 
acquisition. At the conclusion of the experiment, a sample 
of the left ventricle was excised, blotted, and weighed to 
obtain the wet weight. The sample was dried until a 
constant dry weight was achieved. Percent tissue water 
(%TW) was determined by the equation %TW = (wet 
weight - dry weight)/wet weight. 
All animals received humane care in American Associ- 
ation for Accreditation of Laboratory Animal Care-ac- 
credited (No. 00036), United States Department of Agri- 
culture-registered (No. 52-R-007) facilities in compliance 
with the "Principles of Laboratory Animal Care" formu- 
lated by the National Society for Medical Research and 
the "Guide for the Care and Use of Laboratory Animals" 
prepared by the institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 85-23, revised 1985). 
Data analysis. Left ventricular systolic and diastolic 
pressures were determined from the digitized data files 
with the use of software developed in our laboratory. 
End-systolic pressure. The end-systolic pressure (ESP) 
of a beat was defined as the maximum point of the 
digitized pressure waveform. The average ESP was calcu- 
lated by averaging the ESPs of 10 beats. Average ESP 
values were obtained for each balloon volume at baseline 
and postreperfusion. The ESP versus balloon volume 
(BV) data for baseline and postreperfusion were fitted to 
the linear end-systolic pressure-volume r lationship with 
the use of a least squares linear regression algorithm: 
ESP = Ema x X (BV) + k 
where E .. . .  is the slope and k is the y-intercept. 
EDP. The EDP of a beat was defined as the point at 
which the increase in slope of the pressure waveform 
exceeded a threshold of 0.5 mm Hg/msec. This was 
visually confirmed for each beat. The average EDP was 
calculated by averaging the EDP values of 10 beats and 
was obtained for each balloon volume at baseline and 
postreperfusion. The EDP versus balloon volume (BV) 
data were fitted to the linear end-diastolic pressure- 
volume relationship with the use of a least squares linear 
regression algorithm: 
EDP = m(BV - BY0) 
where m is the slope and BV o is the balloon volume 
corresponding to an EDP of zero, or the x-intercept, m' ~ 
A linear representation f the diastolic pressure-volume 
relationships was appropriate over the limited range of 
end-diastolic volumes examined in this model. .2 
Developed pressure. The left ventricular developed pres- 
sure was obtained by subtracting the EDP from the ESP 
for each data point. An average of 10 data points was used 
for each balloon volume. The developed pressure (DP) 
versus balloon volume (BV) data for baseline and pos- 
treperfusion were fitted to a linear pressure-volume rela- 
tionship with use of the following linear regression algo- 
rithm: 
DP - ESP EDP = (Ema x X BV + k) - m(BV - BV0) 
Percent recovery of developed pressure. The percent re- 
covery of developed pressure was calculated as the per- 
centage of the postreperfusion average developed pres- 
sure to the baseline average developed pressure at the 
same balloon volume (BV). This was calculated for each 
of the postreperfusion matched balloon volumes. The 
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Table I. Mechanical and electrical parameters 
Cardioplegic solution 
Time to infuse 
cardioplegic solution (rain) 
Time until Time unitt 
mechanical arrest electrical arrest 
(min)* (min)* 
Krebs-Henseleit 3£8 +- 2.10 5.58 _+ 0.82 18.58 ± 2.10 
St, Thomas' Hospital 2.60 +_ 0.16 7.86 _+ 0,43 15.82 ± 0.13 
50 txmol/L pinacidil 1.93 ± 0.39 7.49 +_ 0.62 16.93 ± 0.39 
Pinacidil plus glibenclamidc 1,89 + 0.36 6.33 + 0.67 18.53 ± 1.67 
Data are represented as mean plus or minus standard error of the mean. 
*Time from onset of 15-minute normothermic ischemic period. 
average percent recovery of developed pressure (%Rec 
DP) was obtained by use ofthe trapezoidal rule13and the 
following equation: 
Average%RecDP = 100 
fBVm~ DP postreperfusion dBV/BVmax - BVmin) 
X ) BVmin ~- -b~ 
where BV~ is the maximum postreperfusion matched 
balloon volume and BV~,, is the minimum postreperfu- 
sion matched balloon volume, s 
Statistical analysis. Values are represented as the 
mean plus or minus the standard error of the mean. 
Analysis of variance was used for comparison of multiple 
groups. A Student's t test (or Mann-Whitney test when 
appropriate) was used to compare two means. A paired 
Student's t test was used to compare means before and 
after an intervention. Differences were considered statis- 
tically significant when p < 0.05. Statistical analysis was 
done with Sigma Stat software (version 1.01, Jandel Corp., 
San Rafael, Calif.). 
Results 
Delivery of cardioplegic solution. The mean time 
to infuse the cardioplegic solution ranged between 
1.89 +_ 0.36 and 3.58 -+ 2.10 minutes and was not 
different among the groups (Table [). 
Temporal aspects of the development of electro- 
mechanical arrest. The mean times for the cessa- 
tion of electrical and mechanical activity are repre- 
sented in Table I for each group. Mechanical arrest 
occurred in all instances during the period of unpro- 
tected, global, normothermic schemia and was not 
different among groups. Electrical quiescence was 
not achieved until after the administration of cold 
cardioplegic solution in all groups. Electrical quies- 
cence was achieved most rapidly in the St. Thomas' 
Hospital group, but this was not significantly shorter 
than in the other groups. 
Postisehemic recovery of systolic function: depo- 
larized versus hyperpolarized arrest. The percent 
recovery of developed pressure in the hearts pro- 
tected with St. Thomas' Hospital solution, pinacidil, 
pinacidit with glibenclamide, and Krebs-Hense[eit 
cardioplegic solution was 46.4% _+ 2.2%, 49.3% + 
2.4%, 43.0% + 4.3, and 32.8% _+ 2.8%, respectively 
(Fig. 1). The percent recovery of developed pressure 
was significantly higher in both the pinacidil and St. 
Thomas' Hospital groups when compared with that 
in the Krebs-Henseleit group (p = 0.009). 
Postischemic recovery of diastolic properties: de- 
polarized versus hyperpolarized arrest. The slopes 
of the diastolic pressure-volume r Iationships at 
baseline and after 30 minutes of reperfusion were 
compared (Table II). There was a statistically sig- 
nificant increase in slope after reperfusion com- 
pared with baseline values in all groups (St. Thomas' 
Hospital, p < 0.001; pinacidil, p = 0.002; pinacidil 
with glibenclamide,p = 0.002; and Krebs-Henseleit, 
p = 0.017). In addition, the Krebs-Henseleit group 
had a significantly higher reperfusion slope as com- 
pared with that of all other groups (p = 0.022). 
Reperfusion arrhythmias. On reperfflsion, no 
hearts underwent ventricular fibrillation. 
Reperfusion coronary blood flow. The mean 
baseline coronary blood flow before ischemia at an 
EDP of 5 mm Hg ranged between 7.0 +- 1.0 and 
9.1 -+ 1.7 ml/min and was not significantly different 
among groups (Fig. 2). Coronary blood flow imme- 
diately on reperfusion was significantly increased 
compared with baseline flow in the St. Thomas' 
Hospital, pinacidil, and pinacidil with glibenclamide 
groups (p = 0.014, p < 0.001, and p = 0.002, 
respectively). The coronary blood flow on reperfu- 
sion was significantly lower in the Krebs-Henseleit 
group compared with that in all other groups (p = 
0.004). 
After 5 and 10 minutes of reperfusion, the coro- 
nary blood flow in the pinacidil group remained 
significantly higher than both the flow at baseline 
and the flow in the Krebs-Henseleit group (p < 
0.001 and p = 0.021, respectively). The coronary 
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Fig. 1. Percent recovery of developed pressure (DP) for the Krebs-Henseleit (Krebs), pinacidil with gliben- 
clamide (Pinacidil + Glib), St. Thomas' Hospital (St. Thomas), and pinacidil groups. Values are represented as 
mean plus or minus the standard error of the mean. *p < 0.05 versus Krebs-Henseleit group. 
blood flow then returned to baseline levels after 15 
minutes of reperfusion. The coronary blood flow in 
the glibenclamide with pinacidil group remained 
elevated compared with its baseline value until 10 
minutes of reperfusion (p = 0.042). 
The coronary blood flow in the St. Thomas' 
Hospital group returned to the baseline level after 5 
minutes of reperfusion. After 30 minutes of reper- 
fusion, the coronary blood flow in the St. Thomas' 
Hospital and Krebs-Henseleit groups declined to a 
level significantly lower than baseline (p = 0.003 and 
p = 0.019, respectively). 
Myocardial tissue water. The mean percent is- 
sue water was 80.4% _+ 0.3%, 80.7% + 0.3%, 80.7% 
_+ 0.5%, and 80.4% _+ 0.1% for the St. Thomas' 
Hospital, pinacidil, pinacidil with glibenclamide, and 
Krebs-Henseleit groups, respectively. There was no 
statistically significant difference in percent tissue 
water among groups. 
Discussion 
PCOs pharmacologically open NAT p channels, 
causing a potassium efflux from the cell, a reduction 
in the action potential duration, and a reduction in 
Table II. Diastolic function 
Cardioplegic Baseline slope Reperfusion slope 
solution (mm Hg/ml) (mm Hg/ml) 
St. Thomas' Hospital 17.85 _+ 1.47 29.26 +_ 3.17"t 
50/xmol/L pinacidil 25.71 _+ 1.73 34.98 _+ 2.47"t 
Pinacidil plus 27.73 _+ 3.35 35.85 _+ 3.49"t 
glibenclamide 
Krebs-Henseleit 27.34 + 6.22 53.22 + 6.88* 
Data are represented asmean plus or minus standard error of the mean. 
*p < 0.05 versus baseline value. 
?p < 0.05 versus Krebs-Henseleit group. 
calcium influx. The resultant contractile arrest has a 
potent cardioprotective effect during periods of isch- 
emia.1, 2, 14 When given before myocardial ischemia, 
PCOs have been demonstrated to improve recovery 
of ventricular function, decrease infarct size, and 
limit high-energy nucleotide loss in various animal 
models,6, 15-17 
The inherent cardioprotective effects of PCOs 
offer advantages over traditional depolarized arrest 
with hyperkalemic cardioplegia. The ongoing meta- 
bolic processes and derangements in transmem- 
brane ionic gradients that occur at depolarized 
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pinacidil and pinacidil with glibenclamide groups versus Krebs-Henseleit group; *p < 0.05 pinacidil versus 
Krebs-Henseleit group. 
potentials represent major shortcomings of tradi- 
tional potassium cardioplegia, is'19 These metabolic 
processes include energy-requiring calcium and so- 
dium pumps that continue to turn over and deplete 
critical energy supplies. 18' 19 Hypothermia became a
standard part of many myocardial protection strat- 
egies to decrease this ongoing metabolic demand. 
The natural resting state of the myocardium is at 
a more negative membrane potential (hyperpolar- 
ized), and at this potential, transmembrane ion 
gradients are largely balanced and net ion flux is 
minimal. In addition, few voltage-gated ion channels 
are open. 1 Thus energy demand is minimized. By 
providing ischemic protection at a more physiologic 
membrane potential, PCOs may be more ideal 
cardioplegic agents than traditional depolarizing 
hyperkalemic solutions. 
Previous work from our laboratory has docu- 
mented the effectiveness of pinacidil as a cardiople- 
gic agent when compared with hyperkalemic cardio- 
plegia consisting of Krebs-Henseleit solution with 20 
mmol/L KC1 during normothermic ischemia nd has 
established the optimal dose of pinacidil (50 
/,mol/L) in an isolated rabbit heart model] How- 
ever, there has been some question as to the efficacy 
of these PCOs under hypothermic conditions. 
Strong experimental evidence is available to support 
this question. The shortening of the action potential 
duration by pinacidil has been shown to be more 
rapid and more complete at 37°C than at 23 ° C. 2° 
Moreover, the outward potassium current activated 
by pinacidil has been shown to cease at 19 ° to 21 ° C 
in isolated guinea pig myocytes. 21
However, previous work has suggested that PCOs 
may be effective as hypothermic cardioplegic agents. 
PCO cardioplegia with pinacidil has been shown to 
provide superior protection compared with hy- 
perkalemic ardioplegia during hypothermic isch- 
emia in an intact porcine model. 22 
This study was designed to examine the effective- 
ness of myocardial protection during surgical global 
hypothermic ischemia in the acutely injured heart 
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with pinacidil and to compare this protection with 
that of the standard hyperkalemic cardioplegia, St. 
Thomas' Hospital solution. KAT e channel activity 
was examined under hypothermic onditions with 
use of the potassium channel inhibitor, gliben- 
clamide. 
Postischemic functional recovery: depolarized 
versus hyperpolarized arrest. Pinacidil and St. 
Thomas' Hospital solution provided superior pro- 
tection during the 50 minutes of hypothermic arrest 
in the acutely injured heart when compared with 
Krebs-Henseleit solution alone. However, there was 
no statistical difference between pinacidil and St. 
Thomas' Hospital solution. Although this is in con- 
trast to findings of a previous tudy, 22 this may be 
explained by the different experimental models and 
protocols and species variation. The improved pro- 
tection with pinacidil was lost with the addition of 
the potassium channel inhibitor glibenclamide. This 
indicates that some NAT P channel activity by this 
drug during hypothermia is responsible for the 
observed cardioprotection. 
The lack of statistical difference in percent recov- 
ery of developed pressure between the pinacidil and 
the pinacidil with glibenclamide groups may be 
related to a suboptimal dose of glibenclamide. 
Postischemic recovery of diastolic properties. 
The end-diastolic pressure-volume relationships 
were linear over the range of volumes tested in our 
experiments, as has been described by other inves- 
tigators.ll, 12 The mean linear regression coefficient 
for the pressure-volume r lationships was 0.99 _+ 
0.00, 0.99 _+ 0.00, 0.99 _+ 0.01, and 0.98 _+ 0.01 for 
the Krebs-Henseleit, Krebs-Henseleit with pinacidil, 
Krebs-Henseleit with pinacidil and glibenclamide, 
and St. Thomas' Hospital groups, respectively. All 
cardioplegia groups showed a significant rise in the 
slope of the pressure-volume relationship after isch- 
emia, indicating a decrease in ventrieular compli- 
ance. The reperfusion slope in the Krebs-Henseleit 
group was significantly greater than that of any other 
group, which suggests a more severe diastolic injury 
in this unprotected group. 
The Krebs-Henseleit group had a more severe 
diastolic injury compared with that in the pinacidil 
with glibenclamide group. This may be because of 
the inability of the 10/xmol/L dose of glibenclamide 
to saturate and block all of the KAT P channels in the 
presence of 50 ixmol/L pinacidil or because of a 
non-KaT E channel-mediated mechanism of protec- 
tion by pinacidil. 
The development of electromechanical arrest. 
Mechanical arrest occurred at approximately the 
same time in all groups. This occurred during the 
15-minute period of unprotected normothermic 
ischemia and therefore no difference would have 
been expected among groups. This is indicative of a 
similar response of the hearts in all groups to 
unprotected ischemia. 
There was no significant difference among groups 
in the time until electrical arrest. This is probably 
because hypothermia lone is effective in eliminat- 
ing electrical activity and this overcame the previ- 
ously observed inability of pinacidil to achieve rapid 
electrical asystole. 
Reperfusion coronary blood flow. Reperfusion 
coronary blood flow in the pinacidil group was 
greater than the coronary blood flow in the Krebs- 
Henseleit group for the initial 10 minutes of reper- 
fusion. The coronary blood flow immediately on 
reperfusion was greater in the St. Thomas' Hospital 
group compared with that in the Krebs-Henseleit 
group but this was not different from that seen with 
pinacidil. These data are in contrast to our previous 
findings after normothermic schemia in which the 
coronary blood flow was significantly higher in the 
PCO-protected groups than in the St. Thomas' 
Hospital group. 7 This may be explained by the 
greater ischemic insult in this protocol (15 minutes 
of normothermic unprotected plus 50 minutes of 
hypothermic protected ischemia) compared with 
that in our previous work under normothermic 
conditions (30 minutes of protected ischemia). The 
increased coronary blood flow in this study in the St. 
Thomas' Hospital group, as opposed to that in the 
previous study, may be the result of a greater 
ischemic insult that resulted in reperfusion hyper- 
emia. This would be consistent with the poorer 
recovery of developed pressure in this study com- 
pared with our previous results and the significant 
diastolic injury seen in each group. 
The pinacidil with glibenclamide group exhibited 
some hyperemia on reperfusion and after 5 minutes 
of reperfusion, which suggests ome KAT e channel 
activity and resultant vasodilation despite the 10 
/xmol/L dose of glibenclamide or a non--KATp chan- 
nel-mediated endothelial protection in this group. 
The shortened period of reactive hyperemia in the 
pinacidil plus glibenclamide group compared with 
that in the pinaeidil group is consistent with the 
inhibition of KAT P channel activity by glibenclamide 
under these hypothermic conditions. 
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The lack of reactive hyperemia in the Krebs- 
Henseleit group alone is also different from that in 
our previous work under normothermic conditions. 
This suggests that the endothelium in the Krebs- 
Henseleit group was unable to provide the expected 
hyperemic response because of the magnitude of the 
injury in this protocol and a no-reflow response. 
However, the changes noted in reperfusion coro- 
nary blood flow in these experiments may be reflec- 
tive of many factors not limited to the vasodilatory 
properties of pinacidil and reactive hyperemia. It is 
likely that the cardioprotective properties of pinaci- 
dil are independent of the vasodilatory properties, 
and further research is indicated to elucidate these 
findings. 
Incidence of ventricular fibrillation on reperfu- 
sion. In contrast o our previous findings with the 
use of PCOs during normothermic ischemia, no 
hearts in this study fibrillated on reperfusion. 7 PCOs 
have been demonstrated to be proarrhythmic by 
decreasing action potential duration and, as a result, 
decreasing the refractory period. 16' 23 This finding 
after hypothermic ischemia may be related to the 
decreased efficacy of pinacidil at lower temperatures 
to open KAT P channels and decrease action poten- 
tial duration. Alternatively, it may represent an 
electrophysiologically protective ffect of hypother- 
mia itself. Further studies will be needed to clarify 
this issue. 
However, both the absence of reperfusion ventric- 
ular fibrillation and the lack of prolonged electrical 
activity by PCO cardioplegia in our study suggest a 
different electrophysiologic effect of pinacidil on 
KAT P channels under these hypothermic conditions. 
Model shortcomings. The advantages and disad- 
vantages of the blood-perfused isolated rabbit heart 
Langendorff model have been previously described. 7' 8 
This model provides a closer approximation to the 
clinical situation than crystalloid-perfused models. 
There are many advantages of blood over crystalloid 
perfusion in the investigation of ischemia/reperfusion 
phenomena. These include a higher oncotic pressure, 
improved oxygen-carrying capacity, the histidine/imi- 
dazole buffering capacity, the presence of free radical 
scavengers, and improved capillary flow distribution. 
The isolated rabbit model has been shown to be quite 
stable over 120 minutes of aerobic perfusion as com- 
pared with that of other animal species. 24 As always, 
care should be taken when extrapolating these data to 
the clinical situation. 
In addition, the optimal dose of pinacidil (50 
/zmol/L) used in these experiments was determined 
with use of a dose-response curve generated with 
normothermic schemia. 7 This dose may not be the 
optimal choice under the conditions of hypothermia 
used in the present experiments. 
Summary. Pinacidil (50 /xmol/L) provided com- 
parable myocardial protection to that of St. Thomas' 
Hospital solution during hypothermic ischemia in 
the blood-perfused rabbit heart model. This protec- 
tion was superior to that of Krebs-Henseleit solu- 
tion. The superior myocardial protection provided 
by pinacidil was lost when glibenclamide was added 
to the cardioplegic solution, indicating KAT P chan- 
nel activity during hypothermia despite previous 
results in isolated myocytes. 2°' as 
In addition, the previously noted proarrhythmic 
nature of pinacidil seen in our normothermic experi- 
ments was absent under the present hypothermic 
experimental conditions. This observation raises ques- 
tions as to the nature of the action of pinacidil under 
hypothermic conditions. This finding is advantageous 
for the future clinical use of these agents in that 
reperfusion ventricular fibrillation, previously noted 
with normothermia, did not occur after hypothermic 
global ischemia protected with pinacidil. 
We gratefully acknowledge the help of Luke Wolfe for 
statistical analysis and the generous donation of pinacidil 
by Leo Pharmaceuticals, Ballerup, Denmark. 
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